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Background: Systemic agents in cancer treatment were often associated with possible infusion reactions (IRs). This
study estimated the incidence of IRs requiring medical intervention and assessed the clinical and economic impacts of
IRs in patients with colorectal cancer (CRC) treated with cetuximab.
Patients and methods: Details on patients with CRC receiving cetuximab in 2004–2006 were extracted from
a large USA administrative claims database. IRs were identiﬁed based on the occurrence of outpatient treatment,
emergency room (ER) visit, and/or hospitalization for hypersensitivity and allergic reactions. Multivariate regressions
were used to examine potential risk factors and quantify the economic impact of IRs.
Results: A total of 1122 CRC patients receiving cetuximab were identiﬁed. The incidence of IRs requiring medical
intervention was 8.4%. Sixty-eight percent of the patients had treatment disruptions and 34% discontinued cetuximab
treatment. Mean adjusted costs were $13 863 for cetuximab administrations with an IR requiring ER visit or
hospitalization and $6280 for those with an IR requiring outpatient treatment, compared with $4555 for those without
an IR.
Conclusions: The incidence rate of cetuximab-related IRs requiring medical intervention in clinical practice was
found to be higher than rates reported in the product label and clinical trials. The clinical and economic impacts of
these IRs are substantial.
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introduction
Infusion reactions (IRs) have been documented with
monoclonal antibodies (MAbs) as well as with other cancer
therapies that are administered i.v. [1, 2]. The severity of IRs
varies from mild itching, ﬂushing, and fever to life-threatening
cardiopulmonary events. In a few extreme cases, deaths have
resulted from severe IRs [2–4].
Severe IRs occurred in 2.3%–5% of patients treated with
cetuximab in clinical trials [2]. Nevertheless, recent studies have
reported higher incidence rates of severe IRs among patients
receiving cetuximab. In a prospective, multicenter time-and-
motion study of patients with cancer using cetuximab,
Schwartzberg et al. [4] found that 7% of patients experienced
severe IRs. O’Neil et al. [5] examined IR rates in patients
treated with cetuximab in medical centers from Tennessee and
North Carolina and found that 22% of patients experienced
severe IRs.
Limited data exist to identify risk factors that might
predispose patients to severe IRs. Atopic history and residence
in the middle southern region of the United States have been
found associated with high incidence of severe IRs [5, 6].
Although the prescribing information for cetuximab indicates
that 90% of severe IRs occurred during the initial cetuximab
administration [7], Needle [8] reported that 33% of patients
with severe IRs experienced events after their second dose of
cetuximab. Lenz [2] also noted that 10%–30% of IRs to MAbs
are delayed and occur in later infusions.
The published literature on the clinical and economic burden
of severe IRs in patients with metastatic colorectal cancer
(CRC) is currently limited. In a time-and-motion study of
patients with cancer, those patients who had an IR required
between 31% and 80% additional staff time [4]. A retrospective
study of patients who suffered severe IRs found that 22% were
hospitalized and had an average length of stay of 4 days [3]. In
addition to increased resource utilization, 87% of oncology
nurses participating in an oncology practice survey reported
that both patients and clinicians feel ‘fear’ and ‘stress’ even with
the occurrence of mild IRs [9]. O’Neil et al. [5] also noted that
the experience of an IR can be traumatic for patients, family
members, and the clinical staff managing these events.
Although some studies begin to provide assessments of the
clinical and economic burden of IRs, only one study estimated
the cost impact of IRs on staff time [4].
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economic impacts of IRs in real-world clinical practice, the
objectives of this study were to (i) estimate the incidence rate
of IRs requiring medical intervention among patients with CRC
treated with cetuximab using a large USA health insurance
claimsdatabase,(ii)evaluatepotentialriskfactorsfordeveloping
IRs, and (iii) quantify the clinical and economic impacts of IRs
during the course of treatment in patients with CRC.
patients and methods
overview
A retrospective observational study was conducted using a large USA claims
database. Study participants were patients with CRC receiving cetuximab
treatment from 2004 to 2006. Cetuximab administrations were examined
for incidence of IRs requiring medical intervention. IRs were identiﬁed
based on multiple indicators including outpatient treatments, emergency
room (ER) visits, and/or hospitalizations for hypersensitivity and allergic
reactions. The clinical impact of IRs was assessed through the identiﬁcation
of treatment disruptions (cetuximab dose delay, reduction, rechallenge, and
permanent discontinuation), and the economic impact was calculated as
the incremental direct costs associated with the IRs. Additionally, risk
factors for developing IRs were explored.
data sources
Data were extracted from MarketScan
  Commercial Claims and Encounter
Database and the Medicare Supplemental and Coordination of Beneﬁts
Database from Thomson Reuters. Combined, these two Health Insurance
Portability and Accountability Act–compliant databases include patient-
level medical and pharmacy claim histories for about 30 million
commercially insured lives in the United States annually. Enrollees in the
MarketScan databases are covered under a variety of plan types, including
both capitated [e.g. health maintenance organization (HMO)] and non-
capitated (e.g. fee-for-service) product lines. The databases capture the full
continuum of insurance-reimbursable services delivered across all care
settings including physician ofﬁce visits, ER visits, hospital stays, and
outpatient pharmacy claims. A comparison of the population demographic
characteristics in the MarketScan database with the overall USA population
with employer-sponsored health insurance as reported in the Medical
Expenditure Panel Survey (MEPS) found minimal differences in the overall
age and gender distributions. Compared with MEPS, patients living in the
western region of the United States are underrepresented in the database
and those in the southern region overrepresented.
eligible patients
Study patients were identiﬁed based on the occurrence of at least one claim
containing a code for cetuximab administration (HCPCS J9055, C9215)
from July 2004 to December 2006. The service date of the ﬁrst cetuximab
claim was deﬁned as the index date. Patients were required to have a CRC
diagnosis (ICD-9-CM codes 153.0–153.4, 153.6–153.9, 154.0, 154.1, and
154.8) and be ‡18 years on the index date. Patients needed to have
continuous medical and pharmacy beneﬁts coverage for the 180 days before
the index date. Patients should have no other cetuximab claims in the 180-
day pre-period. Because bevacizumab, another MAb indicated for CRC, is
also associated with IRs, patients with claims of bevacizumab
administration within 14 days of cetuximab administration were excluded.
A 14-day time window was used because bevacizumab is typically
administered biweekly.
IR identiﬁcation
IRs can be identiﬁed and graded by evaluating changes in health status and
symptoms, or by assessing medical interventions taken to manage IRs.
Given that this study used medical claims data, IRs were identiﬁed
according to IR-related diagnoses and claims indicative of medical
interventions that would be associated with the treatment of an IR. An
algorithm using a combination of three indicators, described in the
following, was applied to each cetuximab administration to identify and
classify IRs. Because close monitoring for up to 72 h is recommended for
patients who experience an IR [10], the time interval for identifying an IR
included the day of cetuximab administration and the subsequent 2 days.
The ﬁrst indicator of an IR was based on outpatient claims with
ICD-9-CM diagnosis codes consistent with the signs and symptoms of
hypersensitivity and allergic reactions, such as anaphylactic shock,
angioneurotic edema, bronchospasm, cardiac arrest, dyspnea, and
hypotension. These signs and symptoms were extracted from the
cetuximab product label [7]. The second indicator was outpatient
treatment based and included medication and procedure codes for
treatments consistent with the management of signs and symptoms of
hypersensitivity and allergic reactions in the outpatient setting [2, 10, 11].
Treatment included epinephrine, inhaled bronchodilators (i.e. short-
acting beta-agonists in aerosolized form), two or more doses of
antihistamines, two or more doses of corticosteroids, two or more
administrations of i.v. ﬂuids, glucagons (in combination with beta-
blockers), oxygen, and vasopressors. The third indicator was based on the
occurrence of an ER visit or inpatient admission.
The algorithm was developed to identify IRs by the intensity of medical
interventions based on the combinations of the three indicators. These
three indicators were examined simultaneously for each cetuximab
administration, resulting in 12 distinct combinations. These 12 groups were
further aggregated into four IR categories: IRs requiring an ER visit or
hospitalization, IRs requiring outpatient medical treatment, inconclusive
IRs, and no IR (Table A1). An IR requiring medical interventions occurred
if (i) there was an ER visit or hospitalization with an admitting diagnosis
consistent with the signs and symptoms of hypersensitivity and allergic
reactions or (ii) there were both outpatient diagnosis and outpatient
treatment consistent with the signs and symptoms of hypersensitivity and
allergic reactions. Because this study focused only on IRs that required
intensive resource use, all other combinations of indicators were deemed as
inconclusive evidence of an IR.
Several variables were constructed to quantify the clinical impact of IRs
requiring medical intervention on the course of CRC treatment, including
dose reduction, dose delay, dose rechallenge, and dose discontinuation.
Dose delay was coded when the number of days between the current
infusion and the following infusion was ‡14 days. As the actual dose of
cetuximab was not consistently available in the database, dose reduction
was determined through analysis of cetuximab payments and deﬁned as
a decrease in payment of at least 10% between successive cetuximab claims.
Dose reductions between the ﬁrst and second cetuximab administrations,
however, were not included due to a loading dose of cetuximab on the
initial infusion. Dose rechallenge was deﬁned as subsequent cetuximab
administration within 2 days of the cetuximab administration being
evaluated. Dose discontinuation was deﬁned as no further cetuximab claims
after the administration being evaluated.
costs of IRs
In the MarketScan databases, costs are deﬁned as the total reimbursed
amount delivered to facilities (e.g. hospitals, laboratories, pharmacies) or
medical professionals (e.g. physicians, nurse practitioners) for the services
delivered. Costs are documented for each individual visit or encounter with
health professionals, each hospitalization, or each prescription ﬁll. The
reimbursed amounts include the health plan-paid amounts and any
applicable patient-paid co-pays, coinsurance, and deductibles. This amount
is sometimes referred to as the ‘allowed amount’. Allowed amounts are
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facilities and providers. Hospitalization payments are often based on
negotiated diagnosis-related group-level fee amounts.
The cost of an IR was deﬁned as the difference between the mean cost per
cetuximab administration with IR requiring medical intervention and that
for those administrations without any IRs. Costs for cetuximab
administrations were calculated for claims of health care resource use
within the 3-day window of the cetuximab administrations being evaluated.
For hospitalizations with an admitting diagnosis consistent with the signs
and symptoms of hypersensitivity and allergic reactions and an admission
date in the 3-day window, the cost of this hospitalization was included. All
costs were converted to constant 2006 USA dollars using the consumer
price index for medical care.
statistical analyses
Baseline patient demographic and clinical variables, including age,
gender, geographic region, insurancet y p e ,r e s i d e n c ei nap o l l e ns t a t e ,
atopic history, site of primary tumor, and use of platinum
chemotherapies, were described a n dc o m p a r e db e t w e e np a t i e n t s
experiencing IRs requiring medical intervention and those having no
IRs. A logistic regression was used to examine potential risk factors
associated with IRs. Variables in the model included patient
demographic and clinical characteristics, Deyo–Charlson comorbidity
index, and whether the infusion was an initial administration of
cetuximab.
Adjusted costs for cetuximab administrations were estimated using
a generalized linear model (GLM) with a gamma distribution and log
link function while controlling for patient demographic and clinical
characteristics. Robust standard error estimates were obtained to
account for the occurrence of multiple infusions per patients.
results
patient characteristics
A total of 1122 patients with CRC received cetuximab during
the study period. Overall, the mean age (standard deviation) of
the patients was 61.2 years (11.8), 55% were male, and nearly
85% lived in an urban setting. Patients had various types of
insurance coverage: 41.9% were enrolled in preferred provider
organization, 31.6% had comprehensive fee-for-services, and
15.5% in an HMO. Approximately 20% of the patients resided
in a pollen state and 13.3% had an atopic history. Seventy
percent of the population had primary tumor at the colon.
Almost half (46%) of the patients had at least one concomitant
platinum chemotherapy administration during their use of
cetuximab.
Patients with IRs requiring medical intervention were
compared with those without any IRs on patient characteristics
(Table 1). Overall, these two groups of patients were similar,
with the exception of age, such that patients with IRs were
slightly younger (57 versus 62 years, P < 0.01).
incidence of IRs and clinical impact
A total of 8.4% (94 of 1122) of the patients treated with
cetuximab experienced at least one IR requiring medical
intervention. Of these 94 patients, 37 (39.4%) required an ER
visit or hospitalization. Of the 37 patients, 35 had a single IR
event and 2 a prior IR event that did not require an ER visit or
hospitalization. The remaining 57 patients with an IR were
managed in outpatient settings. Forty-one percent (39 of 94)
of the patients experienced an IR event during their initial
cetuximab administration. Sixty-eight percent of the
patients experienced cetuximab treatment disruption,
including dose reduction or delay (28.7%), permanent
treatment discontinuation (34.0%), and dose rechallenge
(5.3%). For patients who experienced IRs that required an ER
visit or hospitalization, 52.8% discontinued cetuximab
permanently.
risk factors for IRs
The logistic regression model indicated that after controlling
for other patient characteristics, patients’ residence in a pollen
state [odds ratio (OR): 2.67, 95% conﬁdence interval (CI):
1.27–5.62] and initial administrations (OR: 1.85, 95% CI:
1.26–2.71) were associated with a statistically higher likelihood,
and patient age (OR: 0.96, 95% CI: 0.94–0.98) was associated
with a statistically lower likelihood of having an IR requiring
medical intervention (data not shown). Nevertheless, the effect
of atopic history and concomitant use of platinum
chemotherapy on experiencing an IR did not reach statistical
signiﬁcance.
costs of IRs
The costs for administrations with IRs requiring medical
interventions and for those with no IRs were examined (Table 2).
The unadjusted mean total cost for cetuximab administrations
with IRs requiring hospitalization or ER visits was $15 729 and
for those administrations with IRs managed at outpatient
settings $7206, compared with the mean total cost of $4598 for
administrations without any IR. Table 2 further shows that
nearly $8000 was attributed to the hospital treatment of IRs
requiring an ER visit or hospitalization. Over $2500 was due to
outpatient care for post-IR management, such as
corticosteroids, i.v. ﬂuids, and utilization of the resuscitation
cart (data not shown).
The total costs were also examined through GLM
multivariate regression analysis to adjust for patient
characteristics. These results were similar to those before
multivariate adjustment. The adjusted mean costs were $13 863
and $6280 for cetuximab administrations with IRs requiring an
ER visit or hospitalization and outpatient treatment,
respectively, compared with the mean cost of $4555 for those
without any IRs (Figure 1). Thus, the adjusted incremental
costs of IRs were $9308 when an ER visit or hospitalization was
required and $1725 when only outpatient medical care was
required to treat the IRs, as compared with those without IRs.
Results from the model are presented in Table A2.
discussion
Using a large USA-based health insurance claims database, this
study found that 1 in 12 patients using cetuximab therapy to
treat their CRC experienced IRs that required medical
intervention. This rate is signiﬁcantly higher than the rate
reported in the product label prescribing information.
Treatment of IRs resulted in costs of $1725 per case if affected
patients were treated on an outpatient basis and $9308 per case
if the patient required treatment of the IR in the ER or was
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than two-thirds of the patients with IRs experienced
disruptions in their treatment regimen.
Among CRC patients treated with cetuximab, 8.4%
experienced IRs that required resource-intensive medical
intervention, a rate that is two to three times higher than that of
severe IRs reported in the cetuximab prescribing information
(3%) [7] but lower than 22% reported by O’Neil et al. [5] for
patients from North Carolina and Tennessee. Nevertheless, the
incidence rate found in this study is consistent with the 7%
reported by Schwartzberg et al. [4] in their prospective
multicenter study.
With respect to potential risk factors for IRs, the results of
this study were largely consistent with those reported in
previously published literature. Although the initial cetuximab
infusion was associated with higher risk for IRs, results from
this study showed that nearly half of the IRs requiring medical
intervention occurred beyond the ﬁrst cetuximab infusion. This
is consistent with a study by Needle [8] where 33% of patients
who had severe IRs experienced events after their second dose.
These ﬁndings indicate the importance of close monitoring
following every cetuximab infusion.
Previous research found that the occurrence of IRs may
result in the disruption of cetuximab administrations or
discontinuation of the drug altogether [2, 3]. In our study,
68.1% of patients with severe IRs experienced cetuximab
treatment interruption, of which 34% permanently
discontinued cetuximab treatment. For patients who
experienced severe IRs that required an ER visit or
hospitalization, 52.8% discontinued cetuximab permanently.
These ﬁndings are in line with those found in a retrospective
chart review conducted in 19 USA oncology practice sites [3].
Table 1. Patient characteristics
Characteristics CRC patients with IRs (n = 94) CRC patients without IRs (n = 1028) P value
Mean SD Mean SD
Age, years 57.5 11.1 61.6 11.8 0.001
n% n %
Male 55 58.5 563 54.8 0.490
Colon (versus rectum) 63 67.0 718 69.8 0.572
Urban (versus rural residence) 77 81.9 875 85.1 0.408
Geographic region 0.257
Northeast 3 3.2 98 9.5
North central 31 33.0 324 31.5
South 43 45.7 397 38.6
West 17 18.1 208 20.2
Unknown 0 0.0 1 0.1
Living in pollen-sensitive state 26 27.7 202 19.6 0.062
Allergy history 15 16.0 134 13.0 0.412
Insurance plan type 0.059
Comprehensive FFS 20 21.3 334 32.5
HMO 17 18.1 157 15.3
PPO 49 52.1 421 41.0
POS—capitated 2 2.1 8 0.8
POS—non-capitated 6 6.4 86 8.4
Other/unknown 0 0 22 2.1
Concomitant platinum
chemotherapies use
41 43.6 470 45.7 0.696
CRC, colorectal cancer; FFS, fee-for-service; HMO, health maintenance organization; IR, infusion reaction; PPO, preferred provider organization; POS, point
of service; SD, standard deviation.
Table 2. Costs associated with cetuximab administration by infusion reaction (IR) status
IRs requiring ER visits or hospitalization (n = 37) IRs managed by outpatient treatment (n = 210) No IR (n = 7414)
Mean SD Median Mean SD Median Mean SD Median
Inpatient ($) 7954 15 154 3206 0 0 0 0 0 0
Inpatient LOS 2.14 3.08 1.00 0 0 0 0 0 0
ER ($) 417 741 163 0 0 0 0 0 0
Outpatient ($) 7323 4329 6047 7099 5430 5986 4520 2976 3785
Prescription ($) 36 87 0 107 377 0 78 396 0
Total ($) 15 729 16 429 10 521 7206 5436 6019 4598 3017 3851
LOS, length of stay; ER, emergency room; SD, standard deviation.
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underscored by the fact that cetuximab is often administered to
patients with disease progression following chemotherapy and
thereby have limited treatment options.
Another key objective of this study was to quantify the
economic burden associated with the management of IRs in
cetuximab patients. Compared with cetuximab administrations
without IRs, the mean costs for cetuximab administrations with
IRs requiring an ER visit or hospitalization were more than two
times higher ($13 863 versus $4555), resulting in an
incremental cost of $9308. Even for IRs that were able to be
managed in the outpatient setting, the incremental cost to
payers was $1725, or 40% higher than a cetuximab
administration without an IR.
This study leverages a claims-based data source to identify
IRs that required medical intervention. Whereas previous
studies on cetuximab-related IRs were limited to 100
cetuximab patients, the use of a large claims database allowed
for this observational study of 1122 CRC patients receiving
cetuximab from a geographically diverse sample of patients
residing in different regions of the United States. Previous
studies have shown the validity of using claims data to identify
serious adverse events associated with biological agents,
especially when multiple indicators based on diagnosis codes
and inpatient and outpatient treatments were used [12, 13].
Because only IRs requiring an ER visit, hospitalization, or both
outpatient diagnosis and treatment were analyzed in this study,
we hypothesize that these IR cases may have been severe to life-
threatening adverse events.
Similar to other observational studies, there are limitations to
be considered when interpreting the ﬁndings from this study.
First, there are no designated ICD-9-CM diagnosis codes for
IRs, and therefore, an algorithm was developed for
identiﬁcation of IRs based on medical interventions. To
minimize misclassiﬁcation, this study restricted the
classiﬁcation of IRs to those events with resource-intensive uses.
Only an ER visit or hospitalization with admitting diagnoses of
the signs and symptoms of hypersensitivity and allergic
reactions or both outpatient diagnoses and treatment of these
signs and symptoms could qualify as a severe IR. Other cases
were classiﬁed as inconclusive and excluded from the deﬁnition
of IR, such as those even with an ER visit or hospitalization but
without admitting diagnosis of the signs and symptoms of
hypersensitivity and allergic reactions. Thus, the rate of IRs
requiring medical intervention might be underestimated.
Second, as it is not feasible to completely capture all mild to
moderate IRs based on claims data, the cost ﬁndings from this
study may not be generalizable to IRs as a whole. Third, because
this database did not contain actual dosing information for
cetuximab, the study used the cetuximab payment amount as
a proxy for change in dose. Dose reductions following the
initial administration, however, were ignored because of
standard loading-dose protocols for cetuximab. Fourth, this
analysis was based on a database of commercially insured
patient population; therefore, the results may not be
generalizable to other populations. As described in the ‘Data
Sources’ section, the population in the database is
representative of the overall USA population with employer-
sponsored health insurance, but it does not include patients
who are uninsured or rely exclusively on government-
sponsored health insurances. Nevertheless, over half of the
patients in this study sample were 65 years or older; thus, they
were also covered by USA Medicare—the USA federal
government-sponsored health insurance program. Fifth, this
analysis evaluated only the short-term direct clinical and
economic impacts of IRs. There are likely additional indirect
effects on patients and their caregivers that were not addressed
in this study. Long-term clinical and economic implications for
patient treatment and clinical practice were not investigated
and warrant future research.
Despite these limitations, the database with a large patient
population from geographically diverse health plans in real-
world settings and the claims-based algorithm provide
a valuable tool for research in identifying and quantifying
clinical and economic impacts of IRs.
conclusions
The incidence of cetuximab-related IRs requiring medical
intervention in real-world clinical practice may be two to three
Figure 1. Adjusted costs of cetuximab administrations by IR status. ER, emergency room; IR, infusion reaction.
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labeling and clinical trials. The clinical and economic impacts of
these IRs are substantial, as they often require inpatient treatment
and cause disruption of infusion or discontinuation of therapy.
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appendix
Table A1. Algorithm for identifying infusion reactions (IRs)
Classiﬁcation IR indicators
Hospitalization or ER visit
Outpatient diagnosis of
signs and symptoms for
hypersensitivity and allergic
reactions
Outpatient treatment of
signs and symptoms for
hypersensitivity and
allergic reactions
With admitting diagnosis
consistent with the signs
and symptoms for
hypersensitivity and
allergic reactions
Without admitting diagnosis
consistent the with signs
and symptoms for
hypersensitivity and allergic
reactions
I
R
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r
e
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u
i
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i
n
g
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e
d
i
c
a
l
i
n
t
e
r
v
e
n
t
i
o
n ER visit or
hospitalization
UU U
UU
UU
U
UU U
Outpatient medical
treatment
UU
Inconclusive U U
UU
U
U
U
No IR No indicators
‘U’ stands for occurrence of corresponding indicator.
ER, emergency room.
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1460 | Foley et al. Volume 21| No. 7| July 2010Table A2. Results of generalized linear model for costs of infusion
reactions (IRs)
Independent variable Coefﬁcient SE P value
IRs requiring hospitalization or ER
visit
1.113 0.172 0.000
IRs without hospitalization or ER
visit
0.321 0.082 0.000
Male 0.029 0.031 0.351
Age 20.009 0.002 0.000
Geographic region
Northeast 0.090 0.059 0.126
North central 20.003 0.046 0.940
South (reference)
West 0.018 0.047 0.698
Urban location 0.078 0.040 0.051
Year of ﬁrst infusion
2004/2005 (reference)
2006 20.013 0.029 0.643
Type of health insurance
Comprehensive FFS (reference)
HMO 0.178 0.063 0.005
PPO 0.207 0.058 0.000
POS 0.262 0.083 0.002
Other 0.100 0.059 0.091
Clinical characteristics
Deyo–Charlson comorbidity index 0.016 0.005 0.001
Colon (versus rectal) cancer 20.019 0.034 0.572
History of allergy 20.002 0.044 0.967
Concomitant platinum use 0.016 0.031 0.610
First infusion 0.367 0.030 0.000
Model constant 8.646 0.124 0.000
ER, emergency room; FFS, fee-for-service; HMO, health maintenance
organization; PPO, preferred provider organization; POS, point of service;
SE, standard error.
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